These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28841855)

  • 1. Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
    Tanaka N; Asakawa I; Nakai Y; Miyake M; Anai S; Fujii T; Hasegawa M; Konishi N; Fujimoto K
    BMC Cancer; 2017 Aug; 17(1):573. PubMed ID: 28841855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer.
    Tsubokura T; Yamazaki H; Masui K; Sasaki N; Shimizu D; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Nishikawa T; Okabe H
    Sci Rep; 2018 Jul; 8(1):10538. PubMed ID: 30002393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
    Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
    Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The biochemical recurrence-free rate in patients who underwent prostate low-dose-rate brachytherapy, using two different definitions.
    Tanaka N; Asakawa I; Katayama E; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
    Radiat Oncol; 2014 May; 9():107. PubMed ID: 24885896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Biochemical Control of a Prospective Cohort of Prostate Cancer Patients Treated With Interstitial Brachytherapy Versus Radical Prostatectomy.
    Sanmamed N; Locke G; Crook J; Liu A; Raman S; Glicksman R; Chung P; Berlin A; Fleshner N; Helou J
    Clin Oncol (R Coll Radiol); 2023 Apr; 35(4):262-268. PubMed ID: 36737311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
    Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ
    Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy.
    Niwa N; Matsumoto K; Nishiyama T; Yagi Y; Ozu C; Nakamura K; Saito S; Oya M
    Brachytherapy; 2018; 17(6):899-905. PubMed ID: 30245170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy.
    Dutta SW; Bauer-Nilsen K; Sanders JC; Trifiletti DM; Libby B; Lash DH; Lain M; Christodoulou D; Hodge C; Showalter TN
    Brachytherapy; 2018; 17(3):556-563. PubMed ID: 29519605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
    Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
    Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
    Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
    BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
    Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
    Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis.
    Hayashi N; Osaka K; Muraoka K; Hasumi H; Makiyama K; Kondo K; Nakaigawa N; Yao M; Mukai Y; Sugiura M; Takano S; Ito E; Kaizu H; Koike I; Hata M; Taguri M; Miyoshi Y; Izumi K; Kawahara T; Uemura H
    World J Urol; 2020 Oct; 38(10):2477-2484. PubMed ID: 31875247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kindts I; Stellamans K; Billiet I; Pottel H; Lambrecht A
    Strahlenther Onkol; 2017 Sep; 193(9):707-713. PubMed ID: 28488030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. After low and high dose-rate interstitial brachytherapy followed by IMRT radiotherapy for intermediate and high risk prostate cancer.
    Nakamura S; Murakami N; Inaba K; Wakita A; Kobayashi K; Takahashi K; Okamoto H; Umezawa R; Morota M; Sumi M; Igaki H; Ito Y; Itami J
    BMC Cancer; 2016 May; 16():296. PubMed ID: 27142069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
    Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
    Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
    Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival.
    Lo AC; Morris WJ; Lapointe V; Hamm J; Keyes M; Pickles T; McKenzie M; Spadinger I
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):87-93. PubMed ID: 24331654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.